Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.

1 Oct 2015

Abstract excerpt

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are current treatments for advanced non-small cell lung cancer (NSCLC) harboring activating EGFR gene mutations. Histological or cytological samples are the standard tumor materials for EGFR mutation analysis. However, the accessibility of tumor samples is not always possible and satisfactory in advanced NSCLC patients. Moreover, totality of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Lung Cancer Treatments and Mutations
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26629427
DOI: 10.3978/j.issn.2218-6751.2015.08.09

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.PMID 26629427Read ↗

Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectivesSemantic proximity Read ↗

Role of circulating-tumor DNA analysis in non-small cell lung cancer.Semantic proximity Read ↗

Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer.Semantic proximity Read ↗

Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer.Semantic proximity Read ↗

Circulating Tumour DNA in EGFR-Mutant Non-Small-Cell Lung CancerSemantic proximity Read ↗

The Emergent Landscape of Detecting EGFR Mutations Using Circulating Tumor DNA in Lung Cancer.Semantic proximity Read ↗

Detection of circulating tumor DNA in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Circulating Cell Free Tumor DNA Detection as a Routine Tool forLung Cancer Patient ManagementSemantic proximity Read ↗

Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer.Semantic proximity Read ↗

Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction.Semantic proximity Read ↗

ctDNA for the Evaluation and Management of EGFR-Mutant Non-Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.